Keyphrases
Academic Researchers
33%
Academic Staff
33%
Adaptive Immune Response
26%
Campylobacter Jejuni
33%
Cancer Classification
70%
Clinical Trials
52%
Copy number
27%
Copy number Variation
95%
Dendritic Cells
42%
DNA Vaccine
70%
Downhill Running
27%
Dp71
25%
Drop Jump
33%
Duchenne muscular Dystrophy
100%
Dystrophin
54%
Epigenetics
33%
Epitope
66%
Fc Receptor
86%
FCGR3A
50%
FCGR3B
58%
Fcγ Receptor
44%
Gene Expression
43%
Gene Expression Data
56%
Gene Products
34%
Gene Selection
37%
Generative Artificial Intelligence
33%
Genetic Structure
33%
Gp100
30%
High Mobility Group Box 1 (HMGB1)
37%
Higher Education
25%
Human IgG1
30%
IgG1 Antibody
30%
Immune Response
33%
Immune System
37%
Lipooligosaccharide
33%
Low Affinity
59%
Low-grade Glioma
37%
Machine Learning Approach
37%
Melanoma Patients
56%
Ovarian Cancer
50%
Phase II Trial
33%
Poor Survival
44%
Prognostic Marker
38%
Properdin
33%
Receptor Region
50%
Rheumatoid Arthritis
33%
Single nucleotide Polymorphism
37%
T Cell Response
26%
TRP-2
30%
Tumor
56%
Medicine and Dentistry
Arginine Deiminase
16%
Biological Marker
12%
Campylobacter Jejuni
16%
Cancer
29%
Cancer Types
9%
Cell Survival
9%
Clinical Trial
26%
Dendritic Cell
22%
Diseases
11%
DNA Antibody
16%
DNA Immunization
20%
Downregulation
16%
Duchenne Muscular Dystrophy
66%
Dystrophin
27%
Epitope
50%
Epstein Barr Virus
16%
Fc Receptor
11%
Ganglioglioma
20%
Gene Expression
26%
Gene Expression Profiling
18%
Gene Locus
16%
Gene Product
31%
Gene Transfer
16%
Head and Neck Squamous Cell Carcinoma
16%
High Mobility Group B1 Protein
33%
Human Leukocyte Antigen
16%
Immune Response
15%
Immune System
20%
Immunohistochemistry
15%
Immunology
16%
Immunotherapy
16%
Kaplan Meier Method
9%
Lipooligosaccharide
16%
Malignant Neoplasm
54%
Median Survival Time
15%
Melanoma
51%
Nasopharynx Carcinoma
16%
Neoplasm
42%
Ovarian Cancer
50%
Ovarian Tumor
13%
Overall Survival
23%
Phase I Trials
16%
Phytoestrogen
16%
Progression Free Survival
10%
T Cell
37%
T Lymphocyte Receptor
16%
Tissue Microarray
9%
Tumor Cell
10%
Tumor Model
16%
Tumor Progression
11%
